Keveyis FDA Approval History
FDA Approved: Yes (First approved August 7, 2015)
Brand name: Keveyis
Generic name: dichlorphenamide
Dosage form: Tablets
Company: Taro Pharmaceutical Industries Ltd.
Treatment for: Primary Hyperkalemic and Hypokalemic Periodic Paralysis
Keveyis (dichlorphenamide) is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.
Development Timeline for Keveyis
|Aug 10, 2015||FDA Approves Keveyis (dichlorphenamide) for Primary Hyperkalemic and Hypokalemic Periodic Paralysis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.